Home Tags Contrafect
The Yonkers biotechnology company announces it will begin clinical trials of a treatment for drug-resistant Staph infections.
Each unit from the Yonkers firm’s initial public offering will separate on Friday into one share of common stock, one Class A warrant and one Class B warrant.
Maxim Group L.L.C. exercises its over-allotment option in connection with the biotech company's initial public offering, purchasing 880,333 additional units.
Contrafect Corp., a Yonkers-based biotechnology company, prepares to begin clinical trials on humans of its first bacteria-killing drug.